May 22, 2018
Authored and Edited by Kathryn R. Judson; Thomas L. Irving
On May 9, 2018, FDA issued draft guidance on Uncomplicated Urinary Tract Infections (uUTIs): Developing Drugs for Treatment. The guidance addresses the clinical development of drugs intended to specifically treat uUTIs.
FDA previously issued a separate guidance discussing complicated urinary tract infections (cUTIs), which are distinct from uUTIs. uUTIs, also referred to as acute cystitis, occur in females with normal anatomy of the urinary tract and are characterized by pyuria and a documented microbial pathogen on urine culture.
The guidance provides recommendations on the overall development program and clinical trial designs for drugs to support an indication for the treatment of uUTIs. To demonstrate efficacy, FDA recommends randomized, double-blind, controlled trials in female patients with uUTI, using a superiority or noninferiority design.
Additionally, FDA recommends that the intended trial population should be adult females, across a wide age range, with pyuria and at least two signs or symptoms of uUTI such as: dysuria, urinary frequency, urinary urgency, or suprapubic pain. FDA states that patients with signs or symptoms of systemic illness (e.g. fever greater than 38 degrees Celsius, shaking chills, etc.) or treatment with other effective antibacterial drugs for treatment of the current uUTI should be excluded.
Before patient receipt of drug therapy, the guidance recommends all patients to submit a urine specimen for culture and antimicrobial testing. The guidance states that development of new diagnostic tests may facilitate future clinical trial design and benefit patients by providing earlier diagnosis of causative organisms.
FDA recommends that the primary efficacy endpoint should be based on a responder outcome of clinical and microbiologic response. FDA also states that secondary endpoints will help to evaluate sustained microbiologic success and resolution of all clinical symptoms of uUTI.
Furthermore, FDA discusses developing a detailed statistical analysis plan using various analysis population in uUTI clinical trials such as: Intent-to-treat (ITT) population, the microbiological intent-to-treat (micro-ITT) population, clinically evaluable population, microbiologically evaluable population, and safety population. FDA recommends the micro-ITT population should be considered the primary analysis population for a noninferiority trial. FDA also gives recommendations of sample size for noninferiority trials and superiority trials.
Readers are encouraged to read the draft guidance, also available on FDA’s website. Comments and suggestions regarding the draft guidance should be submitted within 90 days from May 9, 2018.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.